Other companies developing claudin 18.2-targeted therapies include Innovent, which started dosing patients with its IBI343 antibody in a phase 1 trial involving patients with various solid tumours ...

Elevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJ: Boston Saturday, March 22, 2025, 15:00 H ...

The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.

Elevation Oncology Inc. has nixed its lead pipeline product, a claudin 18.2 antibody-drug conjugate (ADC) called EO-3021, on disappointing phase I data, sending shares tumbling by 42% and placing its ...

The company plans to submit a New Drug Application (NDA) for satri-cel to the NMPA in the first half of 2025. "We are fully committed to advancing the preparation work for the NDA submission of ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

or metastatic (has spread to other parts of the body), and claudin-18.2-positive and HER2-negative. Your healthcare professional should talk with you about other treatment options. If you are already ...

Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ ...

Satri-cel was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S. FDA for the treatment of advanced GC/GEJ with Claudin18.2-positive tumors in January 2022.

The company plans to submit a New Drug Application (NDA) for satri-cel to the NMPA in the first half of 2025. "We are fully committed to advancing the preparation work for the NDA submission of ...